Update regarding our Amyotrophic Lateral Sclerosis (ALS) study conducted at Sahlgrenska University Hospital in Gothenburg, Sweden 9 October, 2020 Read More »
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants 14 September, 2020 Read More »
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission 28 August, 2020 Read More »
TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR® 13 March, 2020 Read More »
Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™ 9 March, 2020 Read More »
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital 14 June, 2019 Read More »
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency 30 November, 2018 Read More »
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission 20 August, 2018 Read More »
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board. 5 July, 2018 Read More »
